diabetes glp-1 agonist Receptor Agonists: A Game-Changer for Type 2 Dual GIP/GLP-1 receptor agonists: New

For instance, Liraglutide(1.83 mg) showed relatively lower efficacy, with a weight reduction of only 4.03 kg over 52 weeks compared to the placebo, whereas Retatrutide(6.5 mg) exhibited the highest efficacy, achieving a weight reduction of 13.2 kg compared to the placebo over the same period

This raises the question of whether some patients might require longer treatment to sustain weight loss

[36] Semaglutide-associated kidney injury | Clinical Kidney Journal | Oxford Academic. Accessed: Nov

Abstract Non-alcoholic fatty liver disease and steatohepatitis are highly associated with obesity and type 2 diabetes mellitus

However, clinical data relating to the potential of these drugs to improve bone health is only now beginning to emerge